Edding Genor’s GB268 Wins NMPA IND Approval for Phase II Trial – PD‑1/CTLA‑4/VEGF Trispecific Antibody Plus Chemotherapy Targets First‑Line Advanced Colorectal Cancer

Edding Genor (HKG: 6998) announced that China’s National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for a Phase II clinical trial of GB268 — a PD‑1/CTLA‑4/VEGF trispecific antibody — in combination with chemotherapy as a first-line treatment for unresectable locally advanced or metastatic colorectal adenocarcinoma. The trial enters a setting of pronounced unmet need: approximately 95% of advanced colorectal cancer patients are mismatch repair-proficient/microsatellite stable (pMMR/MSS), a subtype well recognized as insensitive to single-agent immunotherapy, while efficacy gains from traditional chemotherapy and targeted therapies have largely reached a plateau.

Regulatory Milestone

Drug Profile & Mechanism of Action

• Molecule: GB268, a trispecific antibody independently developed within the Edding Genor portfolio.
• Targets: Three distinct nodes engaged by a single molecule — PD‑1 and CTLA‑4 (complementary immune checkpoints governing T-cell activation) and VEGF (the central driver of tumor angiogenesis).
• Checkpoint Rationale: Dual PD‑1/CTLA‑4 blockade aims to broaden and deepen antitumor T-cell responses relative to PD‑1 inhibition alone, a combination concept with established clinical precedent in immunotherapy-sensitive tumors.
• Anti-Angiogenic Rationale: VEGF blockade not only starves tumors of blood supply but may also normalize the tumor vasculature and remodel the immunosuppressive microenvironment, potentially enhancing immune-cell infiltration and the activity of checkpoint blockade. (Mechanistic domain background.)
• Trispecific Format: Integrating all three specificities into one antibody is designed to simplify dosing versus multi-drug combinations while coordinating immune activation with vascular modulation. (Company-characterized design; construct details were not disclosed.)

Disease & Treatment Context – pMMR/MSS Advanced Colorectal Cancer

• Epidemiology of Resistance: Approximately 95% of the advanced colorectal cancer population is pMMR/MSS — in contrast to the small dMMR/MSI‑H minority that responds dramatically to checkpoint inhibitors, the pMMR/MSS subtype is well recognized as insensitive to single-agent immunotherapy.
• Plateaued Standard Care: Efficacy gains from traditional chemotherapy and targeted therapies have largely reached a plateau, leaving first-line outcomes for the dominant patient population broadly unchanged.
• “Cold Tumor” Challenge: pMMR/MSS colorectal tumors are typically immunologically cold, with low T-cell infiltration — the precise barrier a VEGF-modulating, dual-checkpoint trispecific is rationally designed to breach.
• First-Line Stakes: As the initial systemic treatment for unresectable locally advanced and metastatic disease, the first-line setting determines the trajectory of all subsequent therapy — making incremental gains here especially consequential.

Market Impact & Outlook

• Large Addressable Population: Targeting the ~95% pMMR/MSS majority of advanced colorectal cancer positions GB268 at one of the largest — and most therapeutically stagnant — segments in gastrointestinal oncology.
• Trispecific Momentum: The program joins the industry’s accelerating push into multispecific antibodies, extending the PD‑1/VEGF bispecific wave into triple-target formats that add CTLA‑4-mediated costimulation.
• Edding Genor’s Pipeline Strategy: The IND approval advances the company’s next-generation immuno-oncology portfolio into a high-prevalence solid tumor with a combination-with-chemotherapy Phase II path.
• Competitive Landscape: First-line pMMR/MSS colorectal cancer remains unconquered by immunotherapy; multiple bispecific and chemo-combination approaches are in global development, with GB268 differentiating through its trispecific architecture.
• Next Steps: Initiation of the Phase II trial in unresectable locally advanced or metastatic colorectal adenocarcinoma; trial size, endpoints, and timelines were not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding GB268 and the approved Phase II trial in combination with chemotherapy for first-line advanced colorectal adenocarcinoma. IND approval permits trial conduct but does not guarantee clinical success or future marketing approval. Actual results may differ due to risks including trial outcomes, safety and tolerability of trispecific-checkpoint-antiangiogenic combinations, regulatory review, and competitive dynamics.-Fineline Info & Tech